Results 201 to 210 of about 6,221,835 (303)
When Tics and Autism Meet: Phenomenology, Severity, and Treatment Patterns
ABSTRACT Background Tic disorders frequently co‐occur with neurodevelopmental conditions, including autism spectrum disorder (ASD). However, the impact of ASD on tic phenomenology, severity, and treatment patterns remains incompletely understood. Objectives To compare clinical characteristics, tic phenomenology, severity, and treatment patterns in ...
Fatimah Aldurayhim +3 more
wiley +1 more source
This study highlights the cardiovascular and longevity benefits of dietary n‐3 PUFAs in individuals with adverse mental health‐related characteristics, particularly ALA and EPA. The target trial emulation framework further provides evidence, revealing EPA and DHA are associated with a lower early‐onset CVD risk in loneliness, while ALA and EPA are ...
Li Chen +9 more
wiley +1 more source
Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota +14 more
wiley +1 more source
Continuous-flow synthesis of 1,4,6,7-tetrahydro-5<i>H</i>-[1,2,3]triazolo[4,5-<i>c</i>]pyridines towards key intermediates of clinical candidates JNJ-54175446 and zanvipixant (JNJ-55308942) with antidepressant activity. [PDF]
Fülöp Z, Bana P, Greiner I, Éles J.
europepmc +1 more source
Joint Risk Factor Combinations with Additive Interaction Increase the Risk of Parkinson's Disease
Abstract Background Combined effects of multiple risk factors on incident late‐onset Parkinson's disease (PD; LOPD) remain poorly characterized. Objective The objective of this study was to quantify the impact of joint risk exposures and estimate the contribution of potentially modifiable factors to incident LOPD risk.
Andrea Quattrone +5 more
wiley +1 more source
Apathy in Lewy Body Disorders: A Position Paper
Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky +12 more
wiley +1 more source
Abstract Background Ursodeoxycholic acid (UDCA) has shown mitochondrial and neuroprotective effects and has been proposed as a treatment for Parkinson's disease (PD). However, population‐level evidence on its effect on PD risk is lacking. Objectives To compare the risk of incident PD among UDCA initiators versus matched non‐initiators within a ...
Chengsheng Ju +7 more
wiley +1 more source
In Silico Studies and In Vivo MAOA Inhibitory Activity of Coumarins Isolated from Angelica archangelica Extract: An Approach toward Antidepressant Activity. [PDF]
Kaur A +5 more
europepmc +1 more source
Abstract Background Parkinson's disease (PD) is frequently accompanied by neuropsychiatric symptoms (NPS), including cognitive impairment, which often emerge early and co‐occur. Their long‐term evolution remains incompletely characterized, particularly in biomarker‐positive cohorts.
Izabelle Schoen +10 more
wiley +1 more source
This narrative review examines the neurological adverse effects associated with commonly used H1‐antihistamines, focusing on how blood–brain barrier (BBB) penetration and patient age influence central nervous system (CNS) toxicity. The major finding is that first‐generation antihistamines, because of higher CNS penetration, are associated with ...
Syeda Samia Fatima +6 more
wiley +1 more source

